34 results
To compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established peripheral artery disease.
To study whether ticagrelor, added to acetylsalicylic acid, modulates the inflammatory response to the administration of lipopolysaccharide (LPS) in humans in vivo.
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
The aim of this study is to evaluate whether adding edoxaban to aspirin following femoropoplitealendovascular intervention will enable maintenance of vessel patency and prevent restenosisrelative to current treatment with clopidogrel and aspirin.
The primary objective of this study is:To evaluate the efficacy of a regimen containing elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS 9350 versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumarate in HIV 1…
The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects <60 kg with stable coronary artery disease (CAD) versus the…
: The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects >=75 years of age with stable coronary artery disease (CAD)…
The main objective of this study is to investigate the effects of a glucagon challenge on hepatic glucose production, abdominal subcutaneous glucose levels in type 2 diabetes patients with and without oral antidiabetics. In addition, endothelial…
The objective of the study is to gain new insights in the causes of a higher clopidogrel resistence in type II diabetes mellitus patients
The primary objective of this study is to determine whether clopidogrel + best medical treatment is superior to best medical treatment only in preventing:A) cardiovascular death, MI, stroke, or severe ischemia of the coronary or peripheral arterial…
The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects <60 kg with stable coronary artery disease (CAD) versus the…
Firstly, to investigate whether the absolute magnitude of Platelet Inhibition inversely correlates with the number of TCD-detected microemboli during and after CAS in patients who are being pre-treated with either a 300 mg or a 600 mg loading dose…
Primary Objectives:1. To compare the magnitude of baseline (or intrinsic) platelet reactivity between T2DM patients and healthy volunteers using multiple platelet function assays 2. To compare the magnitude of baseline (or intrinsic) platelet…
The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects >=75 years of age with stable coronary artery disease (CAD) versus…
The study will assess the hypothesis that the combination warfarin & clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally safe with…
Primary:To evaluate the efficacy of 0.2 mg/kg/day of clopidogrel versus placebo for the reduction of all-cause mortality and shunt-related morbidity in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary…
- To study the response of active glucagon-like peptide-1 (GLP1), Glucagon, Insulin, C-peptide and growth hormone (GH) and liver gluconeogenesis to a glucagon challenge in healthy volunteers- To study the expression of glucagon receptor mRNA in the…
To evaluate safety of 3-months versus standard 12-months of DAPT
Overall objective:The overall objective is to test the hypothesis that GLP-1 receptor activation of CNS reward and satiety circuits occurs, in the context of food(-related) stimuli, and that this effect is altered in individuals with obesity and…